by Laine Bodnar | Mar 19, 2020
Canada’s strength in regenerative medicine (RM) and cell and gene therapies is a result of efforts that take place from sea to shining sea. Western Canada’s growing RM community significantly increases Canada’s competitiveness on the global playing field through its...
by CCRM Australia | Mar 12, 2020
Dr. Chih Wei Teng is Chief Operating Officer for CCRM Australia and wrote this blog with colleagues Alex Barrington and Dr. Emma Gallaher. To subscribe to the CCRM Australia newsletter: Click here As stem cell therapies move through clinical trials and get closer to...
by Tara Fernandez | Feb 20, 2020
Immunotherapies have been heralded as a revolutionary paradigm shift in how cancer is treated, thanks to the exceptional cancer-killing properties of checkpoint inhibitors and chimeric antigen receptor (CAR) T cells. Today, approved therapies Yescarta™ and Kymriah™,...
by Sara M. Nolte | Feb 14, 2020
We’ve spent a lot of time swooning over CAR T-cells and CRISPR here at Signals, but recently a potential up-and-coming leading lady in the gene and cancer therapy fields has caught our eye. Our interest was piqued by a recent press release from The Max Delbruck Center...
by Stacey Johnson | Feb 7, 2020
After four years of attending Phacilitate Leaders World, I have noticed a few things: the organizers like to hang on to what is popular (like the networking yacht party and afternoon tea – head office is in London, England, after all), but they’re equally keen to...
by Lisa Willemse | Jan 9, 2020
It’s no secret that biology is unpredictable, random and sometimes messy. This is precisely what gives living organisms their singularity and uncanny ability to adapt. But as important as these traits might be in a herd of elephants as they adapt to climate change or...
Comments